細胞因子誘導的殺手細胞(CIK) 是一種新型的免疫活性細胞，CIK 增

細胞因子誘導的殺手細胞(CIK) 是一種新型的免疫活性細胞，CIK 增殖能力強，細胞毒殺作用強。該細胞對腫瘤細胞的識別能力很強，如同導彈，能精確攻擊腫瘤細胞，但不會傷及正常的細胞，並較能改善免疫系統、提高免疫力，尤其對手術後或放化療後患者效果顯著，能消除殘留微小的轉移病灶，防止癌細胞擴散和復發，提高自體免疫力，因此，CIK 細胞被認為是是有效免疫治療方案之一。

結果 (英文) 1:

Cytokine-induced killer cells (CIK) is a new kind of immunocompetent cells, CIK strong proliferation, cell strong toxic effect. The cells were strong ability to identify tumor cells as missiles can accurately attack the tumor cells, but will not harm normal cells, and better able to improve the immune system, improve immunity, especially in patient outcomes after postoperative or chemotherapy significantly, can eliminate residual microscopic metastases, to prevent the proliferation of cancer cells and recurrence, improve self-immunity, therefore, CIK cell is considered to be one of the effective immunization regimens.

結果 (英文) 2:

Cytokine-induced killer cells (CIK) are a new type of immunoactive cells with strong CIK proliferation and strong cell axon. The cell is very capable of recognizing tumor cells, like missiles, can accurately attack tumor cells, but will not hurt normal cells, and can improve the immune system, improve immunity, especially after surgery or chemotherapy patients have significant effect, can eliminate residual small metastatic lesions, prevent cancer cell spread and recurrence, improve autoimmune, so CIK cells are considered to be one of the most effective immunotherapy options.

結果 (英文) 3:

Cytokine induced killer cell (CIK) is a new type of immunocompetent cell. CIK has strong proliferation and cytotoxic effect. This cell has a strong ability to recognize tumor cells. Like a missile, it can attack tumor cells accurately, but it will not hurt normal cells, and it can improve the immune system and immunity, especially for patients after surgery or radiotherapy and chemotherapy. It can eliminate the residual small metastasis, prevent the spread and recurrence of cancer cells, and improve self immunity. Therefore, CIK cells are recognized It is one of the effective immunotherapy.